Vericel Corp (VCEL) is a biotechnology company that specializes in the development and commercialization of cell therapies for the treatment of diseases and conditions that involve the repair, reconstruction, or regeneration of human tissue. As with any investment, conducting a thorough technical analysis of VCEL stock is crucial in determining its potential future performance. By analyzing various technical indicators, investors can gain insight into the stock's current and historical price movements, as well as identify potential trends or patterns.

One such technical indicator is the Relative Strength Index (RSI), which measures the speed and change of price movements. A high RSI value may indicate an overbought condition, while a low RSI value could suggest an oversold condition. By analyzing VCEL's RSI, investors can assess the stock's current momentum and determine if it is a good time to buy or sell.

Vericel (VCEL) Technical Analysis

Get insights into Vericel Corp (VCEL) with technical analysis indicators such as RSI, ADX, MACD, ROC, STOCHRSI, and WILLR. Explore our ratings and make informed decisions about Vericel Corp stock.

Vericel Corp (VCEL) - Technical Analysis Indicators and Ratings

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Vericel

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	62.22	Neutral	22.7%
auto_graphMACD	21.04	Neutral	205.0%
auto_graphCCI	85.39	Neutral	59.5%
auto_graphADX	31.97	Neutral	-
auto_graphATR	20.32	Buy	-
auto_graphWILLR	-27.54	Neutral	156.7%
auto_graphROC	34.54	Neutral	201.9%
auto_graphSTOCHRSI	0.00	Buy	-98.6%

Buy	2	-75.00%
Hold	6	-25.00%
Sell	0	-100.00%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Vericel (VCEL) Technical Analysis

Keep an eye on Vericel

Frequently Asked Questions

What are the technical signals for Vericel (VCEL) stock based on the last 30 days?

Take Your Investments to a Whole New Level